CIK 1620546

Baxalta Inc

EDGAR filings

Customers

None disclosed

Suppliers

1 disclosed

Top supplier share

45%

of NKTR revenue · FY to 2025-12-31

Top supplier by $

$24.9M

NKTR · FY to 2025-12-31

Latest period

Dec 31, 2025

10-K filed 2026-03-13

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 1

Companies that disclose Baxalta Inc as a major customer, as a share of their own revenue. 1 active, 0 lapsed.

Company	% of their revenue	Est. $ from Baxalta Inc	Period	Trend	Status	Source
NKTR NEKTAR THERAPEUTICS	45%	$24.9M	FY 2025-12-31		Active	10-K 2026-03-13
Revenue from Baxalta (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, and UCB represented 45%, 37%, and 14% of our revenue, respectively, for the year ended December 31, 2025. 10-K filed 2026-03-13 Period FY 2025-01-01 to 2025-12-31 (45%)Accession 0001193125-26-104547 Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39%, 18%, 17%, 12% and 10% of our revenue, respectively, for the year ended December 31, 2024. 10-K filed 2026-03-13 Period FY 2024-01-01 to 2024-12-31Accession 0001193125-26-104547

Alerts are coming

Get an email when Baxalta Inc's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.